Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koshy, M.
Right arrow Articles by Matthews, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koshy, M.
Right arrow Articles by Matthews, R. H.
The Oncologist, Vol. 9, No. 2, 137–146, April 2004
© 2004 AlphaMed Press


ORIGINAL PAPER
Gastrointestinal Cancer

Multiple Management Modalities in Esophageal Cancer: Epidemiology, Presentation and Progression, Work-up, and Surgical Approaches

Mary Koshya, Natia Esiashvillia, Jerome C. Landrya, Charles R. Thomas, Jr.b, Richard H. Matthewsc,d

a Emory University School of Medicine, Department of Radiation Oncology, Atlanta, Georgia, USA; b UTHSCSA/San Antonio Cancer Institute, Department of Radiation Oncology, San Antonio, Texas, USA; c Beth Israel/Deaconess Medical Center, Harvard Medical School, Department of Radiation Oncology, Boston, Massachusetts, USA; d Boston VA Health Care Radiation Oncology Service, Boston, Massachusetts, USA

Correspondence: Richard H. Matthews, M.D., Ph.D., Beth Israel/Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. Telephone: 617-232-9500, ext 4457 or ext 5628; Fax: 617-524-0643; e-mail: RHMatthews{at}comcast.net

Annually, approximately 13,200 people in the U.S. are diagnosed with esophageal cancer and 12,500 die of this malignancy. Of new cases, 9,900 occur in men and 3,300 occur in women. In part I of this two-part series, we explore the epidemiology, presentation and progression, work-up, and surgical approaches for esophageal cancer. In the 1960s, squamous cell cancers made up greater than 90% of all esophageal tumors. The incidence of esophageal adenocarcinomas has risen considerably over the past two decades, such that they are now more prevalent than squamous cell cancer in the western hemisphere. Despite advances in therapeutic modalities for this disease, half the patients are incurable at presentation, and overall survival after diagnosis is grim. Evolving knowledge regarding the etiology of esophageal carcinoma may lead to better preventive methods and treatment options for early stage superficial cancers of the esophagus. The use of endoscopic ultrasound and the developing role of positron emission tomography have led to better diagnostic accuracy in this disease. For years, the standard of care for esophageal cancer has been surgery; there are several variants of the surgical approach. We will discuss combined modality approaches in part II of this series.

Key Words. Esophageal carcinoma • Multimodal treatment • Survival • Surgeries




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
H. Zhang, L. Xu, D. Xiao, J. Xie, H. Zeng, Z. Wang, X. Zhang, Y. Niu, Z. Shen, J. Shen, et al.
Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion
J. Clin. Pathol., May 1, 2007; 60(5): 555 - 561.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
J S Nagabhushan, S Srinath, F Weir, W J Angerson, B A Sugden, and C G Morran
Comparison of P-POSSUM and O-POSSUM in predicting mortality after oesophagogastric resections
Postgrad. Med. J., May 1, 2007; 83(979): 355 - 358.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. B. Maxhimer, R. M. Reddy, J. Zuo, G. W. Cole Jr, D. S. Schrump, and D. M. Nguyen
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C)
J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 53 - 63.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews
Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches
Oncologist, April 1, 2004; 9(2): 147 - 159.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement